Kurzrock R, Yap B S, Plager C, Papdopoulos N, Benjamin R S, Valdivieso M, Bodey G P
Am J Clin Oncol. 1984 Aug;7(4):305-7. doi: 10.1097/00000421-198408000-00002.
The efficacy of PALA was evaluated in 22 patients with metastatic soft tissue and bone sarcomas. The 20 evaluable patients had received a median of three prior chemotherapeutic regimens, including an adriamycin combination, to which eight had shown response. PALA was administered at 2-week intervals. Sixteen patients received 6 g/m2 over 1 hour intravenously as their initial dose, while six patients received 5 g/m2. The major side effects were skin rash, stomatitis, diarrhea, nausea, and vomiting. Significant myelosuppression was not seen. Two patients had stabilization of disease for periods of 10 and 13 weeks. At the dose and schedule used in this trial, PALA was not effective against advanced adult sarcoma.
对22例转移性软组织和骨肉瘤患者评估了N-磷酸乙酰-L-天冬氨酸（PALA）的疗效。20例可评估患者此前接受的化疗方案中位数为三种，包括阿霉素联合化疗方案，其中8例有反应。PALA每2周给药一次。16例患者初始剂量为静脉注射6 g/m²，持续1小时，而6例患者接受5 g/m²。主要副作用为皮疹、口腔炎、腹泻、恶心和呕吐。未观察到明显的骨髓抑制。2例患者病情稳定了10周和13周。在本试验所采用的剂量和给药方案下，PALA对晚期成人肉瘤无效。
